Home Blog

PAOG Introduces RelaxRX CBD Targeting $100 Billion Sleep Aid

0

Sandusky, OH, Oct. 18, 2021 (GLOBE NEWSWIRE) — PAO Group, Inc. (OTC Pink: PAOG) today announced the launch of its first CBD nutraceutical product, RelaxRX CBD, a sleep aid.

RelaxRX is available in 30mg Softgels and in an 1800mg Tincture.  The CBD oil is 100% derived from full spectrum whole plant hemp oil and contains no added chemicals. 

The sleep aid market was projected at USD 64.29 Billion in 2019 and is forecast to hit USD 101.7 Billion in 2026.

PAOG has confirmed shipping its first CBD nutraceutical product to its distribution partner, North American Cannabis Holdings, Inc. (OTC Pink: USMJ). The product will soon be for sale online at www.USMJ.com.

PAOG expects revenue to grow rapidly following its first CBD nutraceutical product launch as the company has follow-on products lined up to follow the first product adding to overall sales potential.

PAOG plans to announce its next CBD nutraceutical later this week. 

Last year, PAOG acquired intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960).  PAOG is developing both pharmaceutical and nutraceutical treatments base on this intellectual property.

Learn more about USMJ’s ecommerce site at www.usmj.com.

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION
Contact Us:
Jim DiPrima
(888) 979-2675
info@pao.group

Matica Subsidiary West Island Culture Signs Supply Agreement with Ontario

0

Toronto, Ontario–(Newsfile Corp. – October 18, 2021) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that the Company’s subsidiary, RoyalMax Biotechnology Canada Inc. D.B.A. West Island Culture (“West Island”) has signed a Master Supply Agreement with the Ontario Cannabis Retail Corporation, doing business as the Ontario Cannabis Store (the “OCS”), which is the sole wholesale distributor of cannabis for the province. West Island was selected as part of the OCS’s Limited Release program.

Matica CEO, Boris Ziger states, “We welcome the opportunity to introduce our OUESTTM brand of premium craft cannabis to Ontario. We begin our entry into Canada’s largest cannabis market with our flagship ‘Sweet Demon’, a super premium product that has become an instant classic in the Prairies. It is a privilege to be able to serve the people of Ontario and deliver the kind of rare quality that the market is now demanding.”

About Matica

Matica is a multi-faceted, innovative company in the Quebec cannabis space. Its subsidiary, RoyalMax Biotechnology Canada Inc. is a Dorval, Quebec based Health Canada Licence Holder with standard cultivation licence, standard processing, medical sales and sales licences. Matica continues to work with Yunify Natural Technologies, a Quebec based health and personal care research and innovation company to develop proprietary products for Matica and RoyalMax, including topicals and ionic mists. Through its acquisition of Trichome Treats, an award winning chocolatier, Matica and RoyalMax intend on introducing edibles into the RoyalMax product mix.

For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.

On behalf of the Board of Directors
MATICA ENTERPRISES INC.
Boris Ziger
Boris Ziger, CEO & Chairman

The Company’s public filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Boris Ziger, at:
Telephone: 416-304-9935
E-mail: info@maticaenterprises.com
Website: www.maticaenterprises.com , www.maticammj.com

Disclaimer for Forward-Looking Information

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

This news release contains statements about the Company’s information that may be made available on the S&P Capital IQ Corporation Records Listing Program and the business of Matica that are forward-looking in nature and as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99872

Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx(TM), into Brazil, Mexico, and Canada

0

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease

Oakville, Ontario–(Newsfile Corp. – October 18, 2021) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (CVD), announced today that it is expanding its LANCER trial to include several hospital centers in Brazil, Mexico, and Canada. LANCER is a Phase II/III randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of CardiolRx™ in preventing cardiovascular complications in hospitalized patients with a confirmed diagnosis of COVID-19, and who have pre-existing, or significant risk factors for, cardiovascular disease (CVD).

The LANCER trial is currently enrolling patients at hospital centers in the United States under an Investigational New Drug (IND) application cleared by the U.S. Food and Drug Administration (FDA). Cardiol has now received requisite government approvals from health regulators in Brazil, Mexico, and Canada to initiate several additional hospital centers in these countries. Clinical site activation is underway in Brazil and Mexico and the first hospital centers are initiating patient enrollment. Clinical site selection is also in progress in Canada.

“COVID-19 remains an international crisis and there remains an urgent need to develop new therapeutics to address the immune-mediated inflammation that results from the virus, particularly in high-risk patients with cardiovascular disease,” stated Dr. Guillermo Torre-Amione, Chairman of Cardiol Therapeutics. “With the expansion of the LANCER trial to include prominent clinical research centers in Brazil, Mexico, and Canada, we are now positioned to accelerate patient recruitment into the trial and expedite the path towards our goal of determining the cardioprotective properties of CardiolRx in COVID patients with pre-existing, or significant risk factors for, cardiovascular disease.”

The composite primary efficacy endpoint of the LANCER trial is the difference between the active and placebo groups in the percentage of patients who develop, during the first 28 days following randomization and first dose of study medication, one or more of several common outcomes in this high-risk patient population. These include all-cause mortality, requirement for ICU admission and/or ventilatory support, as well as cardiovascular complications, including the development of heart failure, acute myocardial infarction, myocarditis, stroke, or new sustained or symptomatic arrhythmia.

Patients with COVID-19 primarily present with respiratory symptoms which can progress to bilateral pneumonia and serious pulmonary complications. It is now recognized that the impact of COVID-19 is not limited to the pulmonary system. Individuals with pre-existing CVD or who have risk factors for CVD (such as diabetes, hypertension, obesity, abnormal serum lipids, or age greater than 64) are at significantly greater risk of developing serious disease from COVID-19 and experience greater morbidity. Moreover, such COVID-19 patients are at significant risk of developing cardiovascular complications (such as acute myocardial infarction, cardiac arrhythmias, myocarditis, stroke, and heart failure) during the course of their illness, which are frequently fatal. A therapeutic strategy to prevent or limit the number or severity of both pulmonary and cardiovascular complications is likely to considerably improve outcomes from this disease.

The LANCER trial was designed and is being overseen by an independent Steering Committee, consisting of international thought leaders in inflammatory heart disease. In addition to investigating the pulmonary and cardioprotective properties of CardiolRx in high-risk COVID-19 patients, the trial is expected to generate invaluable clinical data with respect to the therapeutic potential of CardiolRx in the treatment of other inflammatory cardiac disorders, including acute myocarditis and heart failure.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (“CVD”). The Company’s lead product, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is being investigated in a Phase II/III outcomes study (the LANCER trial). The LANCER trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, CVD, and to investigate the influence CardiolRx has on key markers of inflammatory heart disease.

Cardiol has also received clearance from the FDA for its investigational new drug (“IND”) application for a Phase II international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains a leading cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure – a leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are “forward-looking information”. Forward looking information contained herein may include, but is not limited to, statements relating to the expansion of the LANCER trial to include several additional clinical research centers in Brazil, Mexico, and Canada, enabling the Company to accelerate patient recruitment into the trial, and the Company’s focus on developing innovative anti-inflammatory therapies for the treatment of CVD. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions, and is subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance, or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form dated March 31, 2021, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise.

For further information, please contact:

Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

Anu Kher, Media Relations
cardiol@kcsa.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99988

High Tide Secures Non-Dilutive Credit Facility with ATB Financial

0

 

High Tide Inc. (“High Tide” or the “Company“) (TSXV: HITI) (Nasdaq: HITI) (FSE: 2LYA), a leading retail-focused cannabis company with bricks and mortar as well as global e-commerce assets, announced today that it has entered into a credit agreement to establish a revolving credit facility with ATB Financial (“ATB“) in an amount of up to $25 million (comprised of an initial $10 million limit and $15 million accordion, the “Facility“), with an expected interest rate of less than 6% per annum.

“We are extremely pleased to finalize this facility today. We know that our shareholders have been looking forward to us securing non-dilutive financing from a leading Canadian bank, and this is also something that we have been working on for some time as we believe that it provides validation of our improved financial profile,” said Raj Grover, President and Chief Executive Officer of High Tide. “This is great news for our shareholders as this credit facility provides us with the firepower to continue our business growth and acquisitions of quality businesses, which are synergistic with our overall ecosystem, while limiting the dilution of our existing shareholder base. We also expect the facility amount to increase in the future as our EBITDA increases, allowing us to realize arbitrage opportunities through accretive acquisitions while limiting the dilution necessary to fuel expansion. I remain excited about High Tide’s growth prospects for the remainder of 2021 and throughout 2022, and look forward to sharing continued positive developments in our company with our shareholders,” added Mr. Grover.

The Facility, which will become effective by end of business today, will consist of senior secured prime rate loans, U.S. base rate loans, LIBOR loans, letters of credit, Bankers’ Acceptances and a Corporate MasterCard.

The Facility has an initial term of three years and provides High Tide, upon completion of customary conditions, with access to an initial $10 million in capital that can be drawn down at High Tide’s discretion (the “Initial Facility Amount“), and subject to satisfaction of certain conditions, will provide High Tide with access to an additional $15 million in capital. The Company expects to have cleared customary conditions for the first draw by the end of its fiscal year ending October 31, 2021. Proceeds from the Facility are expected to be used to finance acquisitions as well as working capital and for general corporate purposes. Amounts drawn down under the Facility will bear interest calculated on the basis of the Company’s adjusted debt-to-EBITDA ratio, which is expected to yield an effective interest rate of less than 6% per annum.

Separately, the Company also announced that a further $1.0 million of debt has been converted into equity, which brings the Company’s total outstanding debt balance to $27.4 million as of today. Of this amount, only $1.6 million matures during the next 12 months.

Vext Secures Ownership in Manufacturing License in Ohio – Moves the Company Toward Vertical Integration in the State

0

Vext Science, Inc. (“Vext” or the “Company”) (CSE: VEXT) (OTCQX: VEXTF) a cannabinoid brand leader based in Arizona, leveraging its core expertise in extraction, manufacturing, cultivation, and marketing to build a profitable multi-state footprint, today announced that it has received approval to have ownership of a manufacturing operation in Ohio, through a 37.5% ownership interest in APP. In July 2022, the Company expects to apply to the Ohio regulators, through another affiliated joint venture partner (the “Joint Venture”), to transition an operating cannabis dispensary license to the Joint Venture. The combination of these acquisitions, once approved by the Ohio regulators and completed, will move Vext closer to vertical integration in Ohio, which is an attractive limited license state with the potential for a future transition into an adult-use market.

Eric Offenberger, CEO of Vext commented, “We have consistently stated that we see the Ohio market as the Company’s second leg of growth, and with the addition of manufacturing ownership, we are positioned to build a strong position in this high population, limited license state. Additionally, we are in the process of pursuing an Ohio cultivation license, to move to vertical integration in the State, which we expect will ensure the quality of both our products and services, while protecting long-term returns. We expect the next 12 months to bring significant growth for Vext shareholders. Our team is currently in the process of tripling cultivation capacity in Arizona, expanding in Ohio, executing on additional organic growth plans in Arizona, and evaluating a robust pipeline of accretive acquisition opportunities. With a solid operational foundation, an established and proven return on capital framework and one of the most attractive cash flow profiles even among large multi-state operator peers, Vext is positioned to continue generating profitable growth for its shareholders.”

Ohio’s state-sanctioned cannabis sales are expected to be between US$350 million to US$425 million in 2021, under a highly regulated, medical-only framework, compared to US$221.5 million in 2020ii.

Matica Announces Name Change and Share Consolidation

0

Toronto, Ontario–(Newsfile Corp. – October 15, 2021) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that, in connection with the previously announced share consolidation on a thirty (30) for one (1) basis (the “Consolidation”), the Company will be changing its name to West Island Brands Inc. (the “Name Change”).

The common shares are scheduled to begin trading on a post-consolidation basis at market open on October 20, 2021 under the stock symbol “WIB”. The new CUSIP number will be 953400108 and the new ISIN number will be CA9534001081. Following the Consolidation, the Company will have approximately 10,712,484 common shares issued and outstanding.

A letter of transmittal will be sent by mail to registered shareholders advising that the Consolidation and Name Change have taken effect. The letter of transmittal will contain instructions on how registered shareholders can exchange their share certificates or DRS statements evidencing their pre-consolidated common shares for new share certificates or new DRS statements representing the number of post-consolidated common shares to which they are entitled. No action is required by non-registered shareholders (shareholders who hold their shares through an intermediary) to effect the Consolidation and Name Change.

No fractional common shares will be issued upon the Consolidation. In the event a holder of common shares would otherwise be entitled to receive a fractional common share in connection with the Consolidation, the number of common shares to be received by such shareholder will be rounded down to the next whole number if that fractional common share is less than one half (1/2) of a common share, and will be rounded up to the next whole number of common shares if that fractional common share is equal to or greater than one half (1/2) of a common share.

About Matica

Matica is a multi-faceted, innovative company in the Quebec cannabis space. Its subsidiary, West Island Culture is a Dorval, Quebec based Health Canada Licence Holder with standard cultivation licence, standard processing, medical sales and sales licences. Matica continues to work with Yunify Natural Technologies, a Quebec based health and personal care research and innovation company to develop proprietary products for Matica and West Island, including topicals and ionic mists. Through its acquisition of Trichome Treats, an award winning chocolatier, Matica and West island intend on introducing edibles into the West Island product mix.

For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.

For More information on our cannabis brands please visit go-ouest.ca and citoyencannabis.ca

On behalf of the Board of Directors

MATICA ENTERPRISES INC.

Boris Ziger
Boris Ziger, CEO & Chairman

The Company’s public filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Boris Ziger, at:
Telephone: 416-304-9935
E-mail:
info@maticaenterprises.com

Website: www.maticaenterprises.com , www.maticammj.com

Disclaimer for Forward-Looking Information

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

This news release contains statements about the Company’s information that may be made available on the S&P Capital IQ Corporation Records Listing Program and the business of Matica that are forward-looking in nature and as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99869

Hip-Hop Icon & Entrepreneur Rick Ross and Rap Snacks Founders and CEO, James Lindsay, Partner with Green Globe – Hempacco to Launch Hemp Hop, a New Line of Hemp CBD Smokables, Delta 8, and Hemp Rolling Paper

0

Green Globe’s Hempacco (GGII), Rick Ross, and James Lindsay have partnered to develop and manufacture Hemp Hop, a line of hemp smokables with different cannabinoids, Delta 8 products, plus a hemp blunt smoking paper brand. Rick Ross and James Lindsay will bring their varied talents and relationships to the partnership, furthering Hempacco’s mission of Disrupting Tobacco(R)

Highlights of the GGII – Rick Ross partnership

  • Rick Ross has over 27 million followers on social media, including 13 million on Instagram, 4 million on Twitter, 8 million on Facebook, and 2.8 million on YouTube
  • Rick Ross’s partner, James Lindsay, has a wholesale distribution network selling to convenience stores
  • Hempacco – GGII will produce a full line of smokables, including cannabinoid cigarettes and hemp blunt rolling paper
  • Hempacco – GGII and Rick Ross are partnering to manufacture and market herb, spice, and hemp smokables and rolling paper
  • Consumers can enter to win a free carton of Hemp Hop every single week by going to the Hemp Hop website, www.HempHop.shop

San Diego, California–(Newsfile Corp. – October 15, 2021) – Green Globe International Inc. (OTC Pink: GGII) (“GGII”) Hempacco, a wholly-owned subsidiary of GGII, partners with Rick Ross and James Lindsay of Hemp Hop Smokables, LLC., to develop and manufacture a line of hemp blunt smoking paper and Functional Hemp Cannabinoid cigarettes under the new Company Hemp Hop Smokables LLC, furthering Hempacco’s mission of Disrupting Tobacco®.

Cannot view this image? Visit: https://i2.wp.com/grassnews.net/wp-content/uploads/2021/10/hip-hop-icon-entrepreneur-rick-ross-and-rap-snacks-founders-and-ceo-james-lindsay-partner-with-green-globe-hempacco-to-launch-hemp-hop-a-new-line-of-hemp-cbd-smokables-delta-8-and-hemp-rollin.jpg?w=696&ssl=1

Rick Ross Cofounder of Hemp Hop Music Producer and Rap Artist

To view an enhanced version of this graphic, please visit:
https://grassnews.net/wp-content/uploads/2021/10/hip-hop-icon-entrepreneur-rick-ross-and-rap-snacks-founders-and-ceo-james-lindsay-partner-with-green-globe-hempacco-to-launch-hemp-hop-a-new-line-of-hemp-cbd-smokables-delta-8-and-hemp-rollin.jpg

Hemp Hop Smokables, LLC is a new venture started by Hempacco, Co. Inc., together with Rick Ross and James Lindsay, to develop, manufacture, and market a consumer goods line that includes cannabinoid hemp functional cigarettes and hemp wrap smoking rolling paper.

Hemp Hop will give Rick Ross’s fans at least one carton per week plus drop surprise merchandise. Consumers and fans can register to win a FREE carton of CBD cigarettes by going to www.HempHop.shop.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2021/10/hip-hop-icon-entrepreneur-rick-ross-and-rap-snacks-founders-and-ceo-james-lindsay-partner-with-green-globe-hempacco-to-launch-hemp-hop-a-new-line-of-hemp-cbd-smokables-delta-8-and-hemp-rollin-1.jpg?w=696&ssl=1

Hemp Hop Smokables by Rick Ross

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7978/99719_greenglobe1.jpg

“I truly believe in the health benefits of Hemp derived products,” said Rick Ross, co-founder of Hemp Hop Smokables, LLC. “Having had my own health scares, and through my healing process, I decided I would develop a line of smokables to help others with the benefits of Hemp cannabinoids. Working with James Lindsay and Hempacco’s team, including Lue, Jorge, and Sandro, has been fantastic. We’ve already started developing the flavors as well as the look and feel of all the products.”

“Working with Rick Ross and James has been a remarkable experience in professionalism and dedication. The attention to detail Rick brings to the flavoring and developing of the hemp CBD cigarettes and hemp wraps is remarkable,” said Sandro Piancone, CEO and founder of Hempacco.

The partnership allows Hemp Hop to use Hempacco’s team and intellectual property, including patents to flavor, develop, infuse and manufacture hemp cigarettes.

“The name recognition Rick Ross brings to this project is remarkable; just marketing to his base will be an incredible experience. With the help of Rick and James, as well as their entire team, we’re introducing a remarkable new brand this year,” said Jorge Olson, CMO and co-founder of Hempacco.

“This is not my first consumer product. I launched Rap Snacks 27 years ago with the vision to create products that speak to the culture. Now Rap Snacks are sold in supermarkets and convenience stores all over the country. Our network of distributors are ready to welcome the product to their shelves and provide consumers with a product that has cultural representation,” said James Lindsay, co-founder of Hemp Hop Smokables, LLC.

Cannot view this image? Visit: https://i2.wp.com/grassnews.net/wp-content/uploads/2021/10/hip-hop-icon-entrepreneur-rick-ross-and-rap-snacks-founders-and-ceo-james-lindsay-partner-with-green-globe-hempacco-to-launch-hemp-hop-a-new-line-of-hemp-cbd-smokables-delta-8-and-hemp-rollin-2.jpg?w=696&ssl=1

James Lindsey Cofounder of Hemp Hop Smokables

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7978/99719_greenglobe2.jpg

Forward-Looking and Cautionary Statements

This news release may include forward-looking statements including opinions, assumptions, estimates, the Company’s assessment of future plans and operations, including but not limited to information concerning a potential combination with Hempacco and the timing thereof. When used in this document, the words “will,” “anticipate,” “believe,” “estimate,” “expect,” “intent,” “may,” “project,” “should,” and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded based on expectations and assumptions made by the Company. Forward-looking statements are subject to a wide range of risks and uncertainties. Although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to regulatory and third party approvals not being obtained in the manner or timing anticipated; the ability to implement corporate strategies; the state of domestic capital markets; the ability to obtain financing; changes in general market conditions; industry conditions and events; and other factors more fully described from time to time in the reports and filings made by the Company with OTC Markets Group, Inc. or the securities regulatory authorities. Except as required by applicable laws, the Company does not undertake any obligation to update or revise any forward-looking statements publicly. We intend that all forward-looking statements be subject to the safe-harbor provisions of relevant securities laws and considered forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended.

# # #

About Green Globe International Inc. (GGII):
Green Globe and its subsidiaries develop, manufacture, market, and sell Consumer Goods, including herb and hemp smokables rolling paper. It trades on the OTC under the ticker: GGII

Green Globe and its subsidiaries current projects include:

  • Herb and Cannabinoid Cigarettes, including CBD Cigarettes
  • Manufacturing hemp rolling papers called hemp blunts
  • 600 Vending Machines selling and advertising Consumer Goods
  • Online sales of CBD products
  • Joint Ventures with large distributors and celebrities
  • Licensing of filters, paper, and infusion in hemp and other smokables
  • The Real Stuff brand of hemp smokables

About Hempacco, Co. Inc.
Hempacco Co, Inc. is Disrupting Tobacco’s™ nearly $1 Trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing herb, spice, and cannabinoid smokables and rolling paper. Hempacco owns The Real Stuff™ functional hemp cigarette and rolling paper brand.

Hempacco Co., Inc. operational segments include:

  1. Manufacturing of smokables and hemp rolling paper
  2. Smokable technology development and licensing
  3. The Real Stuff brand of functional smokables and rolling paper

Hempacco uses and licenses these patents:

  1. Infuse any cigarette with flavor, aroma, and functionality
  2. Cannabis paper for manufacturing paper, blunts, or cigarettes
  3. Spray terpenes on hemp to manufacture hemp cigarettes

About Hemp Hop Smokables, LLC.
Hemp Hop Smokables is a hemp cannabinoid company developing hemp blunts smoking paper and CBD cigarettes along with other smokables. The company is owned by Hempacco, Co. Inc., and Hemp Hop Global, LLC. with founders Rick Ross and James Lindsay with the mission of changing people’s lives with the benefits of hemp and Disrupt Tobacco in the process.

Add Your Name to The Hempacco Investor Email List
To be added to the GGII investor email list and be kept apprised of all upcoming IR activities, please subscribe using this link: https://newsroom.newsfilecorp.com/lists/8020/490 , or for additional information, please call Investor Relations Partners at 323-380-4500.

You can purchase The Real Stuff Hemp Cigarettes by clicking here or copy-paste https://www.realstuffsmokables.com to your browser and get free samples of our Hemp Blunts. Wholesale distributors and retailers get wholesale pricing by calling (775) 473-1201.

Company Contact:
Founder Sandro Piancone or
Investor Relations
IR@hempaccopackaging.com

Here are other Press Release headlines from GGII – Hempacco:

Green Globe Intl. – Hempacco Licenses Hemp Cigarette Manufacturing Technology to CBD Cigarette Company

Green Globe Intl. Chairman, Dr. Stuart Titus, to Serve as Panelist at 7th CBD Outlook Conference

Green Globe Intl. Signs LOI to Acquire Patent to Make Marijuana Paper

Green Globe Intl. – HempBox Vending Partners with Industry Giant SUZOHAPP to Rollout HempBoxes(TM) Across Its Network

Green Globe Intl. – Hempacco Partners with the Pelican Group to Rollout HempBoxesTM Nationwide

Green Globe Intl. – Hempacco Appoints Industry Veteran Dr. Stuart Titus as Chairman of The Board of Directors

GGII Announces 20 Billion Share Reduction in Issued and Outstanding Common Stock

GGII Green Globe – Hempacco to Be Featured in New Hemp and Cannabis Documentary Debuting at Sonoma Film Festival

GGII Green Globe – Hempacco Announces New Initiative to License Their Technology to Manufacture Cannabis Cigarettes

GGII Green Globe – Hempacco Receives Purchase Order for 250,000 packs of CBD Hemp Cigarettes from Ace & Axle, The Largest in Company History

GGII Green Globe – Hempacco launches CalivibesDelta8.com & Signs Joint Venture Agreement to launch Calivibes Delta8 Hemp Cigarettes with a 50% Ownership Stake

GGII Green Globe – Hempacco to Produce a Portfolio of Flavored Hemp Paper Wraps or Hemp Blunts, with the First Order of $230,000

GGII Green Globe – Hempacco Files Patent Application for Cigarette Filter Infusion Technology for Cannabis, Tobacco, Herb, and Hemp Cigarettes, Furthering Their Mission of Disrupting Tobacco

Green Globe – GGII Licenses Patent for Terpene Spraying Technology from Open Book Extracts, Furthering their Mission of Disrupting Tobacco

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99719

Red Light Holland: Global Comedy Star Russell Peters to Have a Psychedelic Journey with Red Light Holland’s Natural Psilocybin Truffles and Red Light Holland’s Therapist in Amsterdam

0

Red Light Holland to live stream an intimate Russell Peters performance in front of a live audience, after he completes his journey, on multiple social media accounts

Red Light Holland to document Russell Peters moments in The Netherlands, as he will be accompanied by a camera crew

Toronto, Ontario–(Newsfile Corp. – October 15, 2021) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce Russell Peters, the company’s Chief Creative Officer, will be in Amsterdam to experience his first psychedelic journey, in late October, 2021. Russell will be using Red Light Holland’s premium psilocybin truffles and will be guided by Red Light Holland’s therapist and expert psychedelic guide Jeff Hamburg. Peters will be accompanied by a camera crew and will give a special performance in front of a live audience which will be live-streamed on Red Light Holland social media accounts after he completes his journey and integration session. More details about the location and exact times, anticipated to happen in late October 2021, will be released next week.

“I just hope after I deal with all my trauma I still stay funny,” said Russell Peters, Red Light Holland’s Chief Creative Officer. “Seriously though, I’m truly ready for this future journey. I know I’m in the best hands with the Red Light Holland team and I hope what I learn, and ultimately share to the world, will help me and hopefully help others.”

“Russell is a great asset to Red Light Holland not only in his creativity, reach and helping plan strategy, but also in his willingness to be a role model and share his future experience in guided therapy,” said Todd Shapiro, CEO and Director of Red Light Holland. “Red Light Holland is on a mission to take magic truffles from underground to mainstream while promoting the responsible use of psychedelics as a tool for growth. Russell’s candidness about his journey will help us get this important information out to a wider audience and we respect and appreciate Russell’s commitment. I’m looking forward to hanging with him in The Netherlands. He’s assured us it’s the right time for him and he’s comfortable with the set and setting and with sharing his experience to the world.”

“I’m excited to facilitate Russell on his truffle journey. It will be fascinating to hear Russell share his experience with the world since every journey is unique,” said Jeff Hamburg, Red Light Holland Therapist and expert psychedelic facilitator. “I am confident this will be beneficial not only to Russell himself, but to others hearing and learning about the potential benefits of such an experience.”

Red Light Holland and Russell Peters will share more details, about where and when people in the Netherlands can attend the live intimate event and where individuals all around the world can view the live-stream, in the near future.

Forward-Looking Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or their respective subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Examples of such information include statements with respect to: the Russell Peters ability to get to the Netherlands, the anticipated journey facilitated by Jeff Hamburg, the intimate live event featuring Russell Peters and the live-streaming of the event; the commencement and projected date regarding the Company’s ability to ensure the live event will happen on the Company’s social media accounts, the venue for the event; statements about the future of the live session with Russell Peters, Jeff Hamburg providing support, with respect to live journey; and expectations for other economic, business, and/or competitive factors.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, expectations regarding future growth and expansion of the operations of the business; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; risks related to infectious diseases, including the impacts of the COVID-19 pandemic; legal and regulatory risks inherent in the psychedelics industry, including the global regulatory landscape and enforcement related to psychedelics; political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the psychedelics industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com, including the Company’s annual information form for the year ended March 31, 2020.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99809

Matica Announces Share Consolidation

0

Toronto, Ontario–(Newsfile Corp. – October 15, 2021) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) is pleased to announce that, pursuant to a director’s resolution, the Company will be consolidating its issued and outstanding share capital on the basis of every thirty (30) old Common Shares being consolidated into one (1) new Common Share (the “Share Consolidation”). Any fractional shares remaining after giving effect to the Share Consolidation will be cancelled.

As a result, the outstanding Common Shares of the Company will be reduced to approximately 10,712,484. The Company has no other securities outstanding.

New ISIN: CA9534001081

New CUSIP: 953400108

About Matica
Matica is a multi-faceted, innovative company in the Quebec cannabis space. Its subsidiary, West Island Culture is a Dorval, Quebec based Health Canada Licence Holder with standard cultivation licence, standard processing, medical sales and sales licences. Matica continues to work with Yunify Natural Technologies, a Quebec based health and personal care research and innovation company to develop proprietary products for Matica and West Island, including topicals and ionic mists. Through its acquisition of Trichome Treats, an award winning chocolatier, Matica and West island intend on introducing edibles into the West Island product mix.

For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.

For More information on our cannabis brands please visit go-ouest.ca and citoyencannabis.ca

On behalf of the Board of Directors
MATICA ENTERPRISES INC.
Boris Ziger
Boris Ziger, CEO & Chairman

The Company’s public filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Boris Ziger, at:
Telephone: 416-304-9935
E-mail: info@maticaenterprises.com
Website: www.maticaenterprises.com , www.maticammj.com

Disclaimer for Forward-Looking Information

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

This news release contains statements about the Company’s information that may be made available on the S&P Capital IQ Corporation Records Listing Program and the business of Matica that are forward-looking in nature and as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99779

PharmaDrug Announces Positive Research Results for Cepharanthine in the Treatment of Multiple Cancers When Used Alone and in Combination with Chemotherapy

0

  • Cepharanthine reproducibly demonstrates potential as a monotherapy in treating multiple cancers with unsatisfactory treatment options
  • Identified 4 cancer types where cepharanthine provides additive or synergistic inhibitory effects when combined with standard of care (SoC) chemotherapy
  • Continued focus on esophageal cancer as most highly responsive cancer examined
  • FDA IND-enabling animal efficacy studies planned for Q4, 2021 examining cepharanthine efficacy alone, and in combination with, SoC chemotherapy to support Phase 1 and 2 clinical studies

Toronto, Ontario–(Newsfile Corp. – October 15, 2021) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce interim positive results for their preclinical cancer study which evaluated the effectiveness of cepharanthine-2HCl alone, or when used in combination with standard of care (SoC) chemotherapy.

Based on the results of a large in vitro cancer screen, the Company had previously identified a short list of 23 cancers that were highly responsive to cepharanthine-2HCl. PharmaDrug was recently provided results for 17 of the 23 cells lines being evaluated by an independent contract research organization and is pleased to announce that greater than 80% of those short-listed cancers once again displayed sensitivity to cepharanthine-2HCl at, or below levels previously determined to be well tolerated in humans. Thus far, esophageal cancer continues to be the most responsive of all cancers tested; with cepharanthine-2HCl displaying at least 2-times greater potency for esophageal cancer than the next most sensitive cancer type. Novel therapeutics in the oncology space are most often assessed as an ‘add-on’ to SoC agents during clinical development. As such, the current study was designed to evaluate the potential for cepharanthine-2HCl to provide additive or synergistic benefit in such settings. Of the 17 cancer cell lines tested thus far, four instances of drug synergy (cepharanthine+chemotherapy) were revealed.

Daniel Cohen, CEO of PharmaDrug commented, “We are extremely excited about the research results and the potential of cepharanthine to treat various cancers as it allows us to confidently advance our pipeline-in-a-pill strategy for not only infectious diseases, but now also oncology. The current results reinforce the potential of cepharanthine as a monotherapy and now also potentially as a synergistic agent when combined with SoC for the treatment of cancer. As such, the primary focus in our oncology program will continue to be esophageal cancer, for which we have already received FDA orphan drug designation. Encouraged by these recent findings, IND-enabling animal efficacy studies to support future human clinical studies in oncology will commence in November.”

That esophageal cancer was shown to be the most highly responsive cancer examined further validates the Company’s motivation to expeditiously advance the clinical development of its patented enteric-coated oral formulation of cepharanthine (PD-001) for esophageal cancer and leverage the benefits of its FDA orphan drug designation granted by the FDA earlier this year. Furthermore, the Company intends to use data from the current study, including identification of synergistic drug combinations (cepharanthine+chemo) to file new intellectual property. In anticipation of the positive research results, the Company has recently manufactured a non-GMP lot of PD-001 for planned animal efficacy studies in oncology and will commence production of a cGMP PD-001 lot to support its upcoming IND-enabling studies and potential FDA Phase 1 and Phase 2 clinical studies in 2022.

Rational Use of Cepharanthine to Treat Cancer

PharmaDrug’s cancer program is based on cepharanthine’s known anti-cancer activities. Cepharanthine has been shown in multiple preclinical efficacy models to inhibit cancer cell proliferation, induce cancer cell apoptosis (death) and restore cancer cell sensitivity to multiple unrelated classes of chemotherapy. Multidrug resistance in particular, continues to represent a considerable clinical challenge. As such, preclinical cancer studies aimed at elucidating the mechanisms that underly chemoresistance; including the critical role drug efflux pumps play in this phenomenon by reducing the intracellular concentration of chemotherapeutic drugs, are of particular interest to PharmaDrug. Cepharanthine has been shown in preclinical studies to potently reverse chemoresistance by downregulating expression of ABCB1, the transcript of which codes for multidrug resistance protein 1, (MDR1, aka P- glycoprotein). Importantly, several prior in vitro and in vivo studies have shown that cepharanthine-mediated reductions in ABCB1 expression restores cancer cell sensitivity to a range of chemotherapeutics including taxanes, vinca alkaloids and platinum-based drugs14. Collectively the studies currently being undertaken by the Company aim to identify and provide focus to novel opportunities in oncology by revealing optimal drug combinations and situations where PD-001 can prevent, lessen, or reverse chemoresistance, and/or provide additive or synergistic benefit to existing treatments. PharmaDrug’s planned animal efficacy studies, designed around the outcome of the current in vitro study, are most ideally suited to experimentally examine the role of cepharanthine in restoring chemosensitivity.

About PD-001 (Enteric-coated Cepharanthine)

Cepharanthine is a natural product and an approved drug used for more than 70 years in Japan to successfully treat a variety of acute and chronic diseases. In clinical research, Cepharanthine has been shown to exhibit multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic effects5,6. However, historically cepharanthine’s low oral bioavailability has represented a major obstacle to realizing its full clinical potential.

The Company is focused on advancing the clinical development of an improved oral formulation of Cepharanthine (PD-001) to treat rare cancers and infectious diseases. Compared to generic Cepharanthine, PD-001 has been shown in rodent and non-rodent models to possess markedly superior bioavailability (more easily absorbed). These findings support the development of an orally administered formulation, and in so doing, removes the undesirable requirement for frequent intravenous dosing.

About PharmaDrug Inc.

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. The Issuer owns 100% of Pharmadrug Production GmbH (“Pharmadrug Production”), a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union. PharmaDrug recently acquired Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial 3rd party validated potential for the treatment of Covid-19 and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Issuer also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms, and psilocybin mushrooms where federally legal, as natural based medicines.

For further information, please contact:

Daniel Cohen, Chairman and CEO
dcohen@pharmadrug.co
(647) 202-1824

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains “forward-looking information” within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. Generally, forward-looking information may be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. In particular, this press release contains forward-looking information in relation to: the timing of the proposed non-clinical and clinical manufacturing of Cepharanthine for the Company’s rare cancer and infectious diseases programs; the ability to expedite development timelines by leveraging SwRI’s existing Cepharanthine preclinical data sets and manufacturing know-how; the ability to advance clinical development of an improved oral formulation of Cepharanthine to treat rare cancers and infectious diseases; the ability to obtain applicable approval for the use of Cepharanthine to treat esophageal cancer; the timing and potential results of the Company’s plan to initiate high throughput studies to screen a large panel of additional cancers; the Company’s plans to evaluate the benefit of its novel oral formulation of Cepharanthine in an animal model of SARS-CoV-2 infection and its proposed discussions with regulators regarding same. This forward-looking information reflects the Company’s current beliefs and is based on information currently available to the Company and on assumptions the Company believes are reasonable. These assumptions include, but are not limited to the ability of the Company to successfully execute on its plans for the Company and Sairiyo; the ability to complete the studies referenced herein and the results thereto; the ability to obtain required regulatory approvals and the Company’s continued response and ability to navigate the COVID-19 pandemic being consistent with, or better than, its ability and response to date.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company’s future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals; risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions; and a deterioration of financial markets that could limit the Company’s ability to obtain external financing.

A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR website at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

References:

  1. Saito T, Hikita M, Kohno K, Tanimura H, Miyahara M, Kobayashi M. Enhanced expression of the multidrug resistance gene in vindesine-resistant human esophageal cancer cells. Oncology. 1994 Sep-Oct;51(5):440-5. doi: 10.1159/000227380. PMID: 8052486.
  1. Zhou P, Zhang R, Wang Y, Xu D, Zhang L, Qin J, Su G, Feng Y, Chen H, You S, Rui W, Liu H, Chen S, Chen H, Wang Y. Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals. Oncotarget. 2017 Nov 27;8(67):111144-111160. doi: 10.18632/oncotarget.22676. Erratum in: Oncotarget. 2021 Jan 05;12(1):61-62. PMID: 29340044; PMCID: PMC5762312.
  1. Huang CZ, Wang YF, Zhang Y, Peng YM, Liu YX, Ma F, Jiang JH, Wang QD. Cepharanthine hydrochloride reverses P glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway. Oncol Rep. 2017 Oct;38(4):2558-2564. doi: 10.3892/or.2017.5879. Epub 2017 Aug 4. PMID: 28791369.
  1. Zahedi P, De Souza R, Huynh L, Piquette-Miller M, Allen C. Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer. Mol Pharm. 2011 Feb 7;8(1):260-9. doi: 10.1021/mp100323z. Epub 2010 Dec 17. PMID: 21166459.
  1. Bailly C. Cepharanthine: An update of its mode of action, pharmacological properties and medical applications. Phytomedicine. 2019 Sep;62:152956. doi: 10.1016/j.phymed.2019.152956. Epub 2019 May 10. PMID: 31132753; PMCID: PMC7126782.
  1. Rogosnitzky M, Danks R. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions. Pharmacol Rep. 2011;63(2):337-47. doi: 10.1016/s1734-1140(11)70500-x. PMID: 21602589.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99792